Complete hematological and major molecular response through treatment with low‐dose Interferon alpha 2a in high‐risk polycythemia vera patient: a case report
Abstract Low‐dose interferon‐α 2a treatment may be considered as an alternative to cytoreductive therapy with hydroxyurea or regularly dosed interferon in high‐risk polycythemia vera patients.
Guardado en:
Autores principales: | Christoph Driessen, Christoph Noppen, Georg Boonen, Juergen Drewe |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5c0ee879362c4452a3469335c3c0f0a6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Polycythemia Vera (PV): Update on Emerging Treatment Options
por: Benevolo G, et al.
Publicado: (2021) -
Ruxolitinib: a targeted treatment option for patients with polycythemia vera
por: Vaddi K, et al.
Publicado: (2016) -
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera
por: Monica Barone, et al.
Publicado: (2021) -
New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options
por: Domenico Penna
Publicado: (2021) -
Nocturnal Mean Oxygen Saturation Is Associated with Secondary Polycythemia in Young Adults with Obstructive Sleep Apnea, Especially in Men
por: Li N, et al.
Publicado: (2019)